Daniel Y C Heng

61 Differential Pattern of Disease Recurrence in Resected Renal Cell Carcinoma Patients Treated with Adjuvant Pembrolizumab Versus Observation: A Propensity Score-Weighted Analysis

Liliana Ascione, Marco Stellato, Alessio Polymeropoulos, Elena Verzoni et autres

Abstract Background Adjuvant pembrolizumab is the standard of care for patients with resected intermediate-high-risk, high-risk, and M1 no evidence of disease (NED) renal cell carcinoma (RCC). Nevertheless, approximately 30% of treated patients experience disease recurrence. Data on patterns of disease recurrence in …

us, it, cz, br, au (code pays fourni par la source)

34 Belzutifan Plus Lenvatinib Versus Cabozantinib in Post–PD-(L)1 Renal Cell Carcinoma: Health-Related Quality-of-Life Outcomes in the Phase 3 LITESPARK-011 Study

Manuela Schmidinger, Daniel Y C Heng, Ray McDermott, Se Hoon Park et autres

Abstract Background Belzutifan plus lenvatinib significantly improved progression-free survival and objective response rate versus cabozantinib, and had manageable safety, in participants with advanced renal cell carcinoma (RCC) that progressed on or after anti-programmed cell death protein 1 and anti-programmed cell death ligand …

at, ca, ie, kr, it, us, jp, br, pl, be, co, es, ps (code pays fourni par la source)

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial

Robert John Motzer, Raymond S. McDermott, Se Hoon Park, Mauricio Burotto et autres

us, ie, kr, it, ps, es, jp, co, be, au, ca, pl, nl, br, at (code pays fourni par la source)